Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA)

European Journal of Pharmaceutical Sciences

Volumn 31, Issue 1, 2007, Pages 53-61

  Van, Linh M ^a   Swales, John ^b   Hammond, Clare ^b   Wilson, Claire ^b   Hargreaves, Judith A ^b   Rostami Hodjegan, Amin ^a,c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c CERTARA UK LIMITED   (United Kingdom)

Author keywords

CYP2D6 inhibition; MDMA; Mechanism based inhibition; Metabolic drug drug interactions

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CYTOCHROME P450 2D6; DEXTROMETHORPHAN;

ARTICLE; CELL COUNT; CONTROLLED STUDY; CRYOPRESERVATION; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; LIVER CELL; LIVER MICROSOME; PRIORITY JOURNAL;

ALGORITHMS; CELL COUNT; CELL SURVIVAL; CRYOPRESERVATION; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DEXTRORPHAN; ENZYME INHIBITORS; ENZYME STABILITY; HEPATOCYTES; HUMANS; KINETICS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; QUINIDINE; TIME FACTORS;

EID: 34247152053     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2007.02.005     Document Type: Article

References (22)

1. Ghanbari F., Rowland-Yeo K., Bloomer J.C., Clarke S.E., Lennard M.S., Tucker G.T., and Rostami-Hodjegan A. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr. Drug Metab. 7 (2006) 315-334
2. Gibbs M.A., Kunze K.L., Howald W.N., and Thummel K.E. Effect of inhibitor depletion on inhibitory potency, tight binding inhibition of CYP3A by clotrimazole. Drug Metab. Dispos. 27 (1999) 596-599
3. Grime K., and Riley R.J. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr. Drug Metab. 7 (2006) 251-264
4. Heydari A., Rowland-Yeo K., Lennard M.S., Ellis S.W., Tucker G.T., and Rostami-Hodjegan A. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab. Dispos. 32 (2004) 1213-1217
5. Hollenberg P.F. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab. Rev. 34 (2002) 17-35
6. Ito K., Iwatsubo T., Kanamitsu S., Nakajima Y., and Sugiyama Y. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 461-499
7. Li A.P., Lu C., Brent J.A., Pham C., Fackett A., Ruegg C.E., and Silber P.M. Cryopreserved human hepatocytes, characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chemico-Biol. Interact. 121 (1999) 17-35
8. Mayhew B.S., Jones D.R., and Hall S.D. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos. 28 (2000) 1031-1037
9. McGinnity D.F., Berry A.J., Kenny J.R., Grime K., and Riley R.J. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab. Dispos. 34 (2006) 1291-1300
10. McGinnity D.F., Soars M.G., Urbanowicz R.A., and Riley R.J. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab. Dispos. 32 (2004) 1247-1253
11. Nichols D.E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class, entactogens. J. Psychoactive Drugs 18 (1986) 305-313
12. Obach R.S. Nonspecific binding to microsomes, impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine and propanolol. Drug Metab. Dispos. 25 (1997) 1359-1369
13. Rowland, A., Gaganis, P., Elliot, D.J., Mackenzie, P.I., Knights, K.M., Miners, J.O., 2007. Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 (UGT2B7) activity by albumin: implications for in vitro-in vivo extrapolation. J. Pharmacol. Exp. Ther. Jan 19, [Epub ahead of print] (doi:10.1124/jpet.106.118216).
14. Silverman R.B. Mechanism-based enzyme inactivation. Chemistry and Enzymology (1998), CRC Press Inc., Boca Raton, FL
15. Takashima T., Murase S., Iwasaki K., and Shimada K. Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers. Drug Metab. Pharmokinet. 20 (2005) 177-182
16. van de Weide J., and Steijns L.S. Cytochrome P450 enzyme system, genetic polymorphisms and impact on clinical pharmacology. Ann. Clin. Biochem. 36 (1999) 722-729
17. Van L.M., Heydari A., Yang J., Hargreaves J., Rowland-Yeo K., Lennard M.S., Tucker G.T., and Rostami-Hodjegan A. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy). J. Psychopharmacol. 20 (2006) 834-841
18. Wu D., Otton v., Inaba T., Kalow W., and Sellers E.M. Interactions of amphetamine analogs with human liver CYP2D6. Biochem. Pharmacol. 53 (1997) 1605-1612
19. Yamazaki M., Suzuki H., and Sugiyama Y. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm. Res. 13 (1996) 497-513
20. Yang J., Jamei M., Heydari A., Yeo K.R., De La Torre R., Farre M., Tucker G.T., and Rostami-Hodjegan A. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J. Psychopharmacol. 20 (2006) 842-849
21. Yang J., Jamei M., Yeo K.R., Tucker G.T., and Rostami-Hodjegan A. Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol. Eur J Pharm Sci. 26 (2005) 334-340
22. Zhao P., Kunze K.L., and Lee C.A. Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab. Dispos. 33 (2005) 853-861